Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors

Molecular Pharmacology

Volumn 80, Issue 2, 2011, Pages 294-303

  Thal, David M ^a   Yeow, Raymond Y ^a   Schoenau, Christian ^b   Huber, Jochen ^b   Tesmer, John J G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BALANOL; CARDIOTONIC AGENT; CMPD 101; CMPD 103A; G PROTEIN COUPLED RECEPTOR KINASE 2; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; IC 50; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATTLE; CRYSTALLOGRAPHY, X-RAY; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 79960223285     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.071522     Document Type: Article

References (42)

1. 2- adrenoceptor as substrates and inhibitors of the β-adrenoceptor kinase. Br J Clin Pharmacol 30 (Suppl 1):3S-12S.
2. Benovic JL, Stone WC, Caron MG, and Lefkowitz RJ (1989) Inhibition of the β-adrenergic receptor kinase by polyanions. J Biol Chem 264:6707-6710. (Pubitemid 19114776)
3. Bogoyevitch MA and Fairlie DP (2007) A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 12:622-633. (Pubitemid 47238645)
4. Boguth CA, Singh P, Huang CC, and Tesmer JJ (2010) Molecular basis for activation of G protein-coupled receptor kinases. EMBO J 29:3249-3259.
5. Bonn S, Herrero S, Breitenlechner CB, Erlbruch A, Lehmann W, Engh RA, Gassel M, and Bossemeyer D (2006) Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity. J Biol Chem 281:24818-24830. (Pubitemid 44274255)
6. Breitenlechner CB, Bossemeyer D, and Engh RA (2005a) Crystallography for protein kinase drug design: PKA and SRC case studies. Biochim Biophys Acta 1754:38-49. (Pubitemid 41797685)
7. Breitenlechner CB, Friebe WG, Brunet E, Werner G, Graul K, Thomas U, Künkele KP, Schäfer W, Gassel M, Bossemeyer D, et al. (2005b) Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J Med Chem 48:163-170. (Pubitemid 40105257)
8. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12-21.
9. Dorn GW 2nd (2009) GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med 87:455-463.
10. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. (Pubitemid 41742764)
11. Huang CC, Yoshino-Koh K, and Tesmer JJ (2009) A surface of the kinase domain critical for the allosteric activation of G protein-coupled receptor kinases. J Biol Chem 284:17206-17215.
12. Iino M, Furugori T, Mori T, Moriyama S, Fukuzawa A, and Shibano T (2002) Rational design and evaluation of new lead compound structures for selective βARK1 inhibitors. J Med Chem 45:2150-2159. (Pubitemid 34525795)
13. Ikeda S, Keneko M, and Fujiwara S (2007), inventors; Takeda Pharmaceutical Company Ltd., Ikeda S, Keneko M, and Fujiwara S, assignees. Cardiotonic agent comprising GRK inhibitor. World patent WO2007034846. 2007 March 29.
14. Johnson LN (2009) Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 42:1-40.
15. Kim CM, Dion SB, Onorato JJ, and Benovic JL (1993) Expression and characterization of two β-adrenergic receptor kinase isoforms using the baculovirus expression system. Receptor 3:39-55.
16. Koide K, Bunnage ME, Gomez Paloma L, Kanter JR, Taylor SS, Brunton LL, and Nicolaou KC (1995) Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol. Chem Biol 2:601-608.
17. Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, Tyka M, Baker D, and Karplus K (2009) Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins 77 (Suppl 9):114-122.
18. Krupnick JG and Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319. (Pubitemid 28231497)
19. Kunapuli P, Onorato JJ, Hosey MM, and Benovic JL (1994) Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5. J Biol Chem 269:1099-1105. (Pubitemid 24032491)
20. Laskowski RA, MacArthur MW, Moss DS, and Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
21. Lodowski DT, Barnhill JF, Pitcher JA, Capel WD, Lefkowitz RJ, and Tesmer JJ (2003a) Purification, crystallization and preliminary X-ray diffraction studies of a complex between G protein-coupled receptor kinase 2 and Gβ1γ2. Acta Crystallogr D Biol Crystallogr 59:936-939. (Pubitemid 36599379)
22. Lodowski DT, Pitcher JA, Capel WD, Lefkowitz RJ, and Tesmer JJ (2003b) Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gβγ. Science 300:1256-1262. (Pubitemid 36618232)
23. Manning G, Whyte DB, Martinez R, Hunter T, and Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934. (Pubitemid 35425239)
24. Mezzasalma TM, Kranz JK, Chan W, Struble GT, Schalk-Hihi C, Deckman IC, Springer BA, and Todd MJ (2007) Enhancing recombinant protein quality and yield by protein stability profiling. J Biomol Screen 12:418-428.
25. Murshudov GN, Vagin AA, and Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. (Pubitemid 27235885)
26. Narayana N, Diller TC, Koide K, Bunnage ME, Nicolaou KC, Brunton LL, Xuong NH, Ten Eyck LF, and Taylor SS (1999) Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase. Biochemistry 38:2367-2376.
27. Noble ME, Endicott JA, and Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805. (Pubitemid 38374863)
28. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. (Pubitemid 27085611)
29. Palczewski K, Kahn N, and Hargrave PA (1990) Nucleoside inhibitors of rhodopsin kinase. Biochemistry 29:6276-6282. (Pubitemid 20222246)
30. Palczewski K, McDowell JH, and Hargrave PA (1988) Purification and characterization of rhodopsin kinase. J Biol Chem 263:14067-14073.
31. Papermaster DS (1982) Preparation of antibodies to rhodopsin and the large protein of rod outer segments. Methods Enzymol 81:240-246.
32. Rabiller M, Getlik M, Kluter S, Richters A, Tuckmantel S, Simard JR, and Rauh D (2010) Proteus in the world of proteins: conformational changes in protein kinases. Arch Pharm (Weinheim) 343:193-206.
33. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, and Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942.
34. Schuttelkopf AW and van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355-1363. (Pubitemid 41079731)
35. Sequist LV and Lynch TJ (2008) EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 59:429-442. (Pubitemid 351287947)
36. Setyawan J, Koide K, Diller TC, Bunnage ME, Taylor SS, Nicolaou KC, and Brunton LL (1999) Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily. Mol Pharmacol 56:370-376. (Pubitemid 29347613)
37. Singh P, Wang B, Maeda T, Palczewski K, and Tesmer JJ (2008) Structures of rhodopsin kinase in different ligand states reveal key elements involved in G protein-coupled receptor kinase activation. J Biol Chem 283:14053-14062.
38. Tesmer JJ, Tesmer VM, Lodowski DT, Steinhagen H, and Huber J (2010) Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. J Med Chem 53:1867-1870.
39. q-GRK2- Gβγ complex. Science 310:1686-1690.
40. Winn MD, Isupov MN, and Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57:122-133. (Pubitemid 32062682)
41. Winstel R, Ihlenfeldt HG, Jung G, Krasel C, and Lohse MJ (2005) Peptide inhibitors of G protein-coupled receptor kinases. Biochem Pharmacol 70:1001-1008. (Pubitemid 41262075)
42. Zuccotto F, Ardini E, Casale E, and Angiolini M (2010) Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 53:2681-2694.